Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
Polyendocrine metabolic ovarian syndrome — новое название для синдрома поликистозных яичников: многоэтапный глобальный консенсусный процесс
2026-05-12
SCID: 54.1/uk4nrj8x
Discuss with AI
Modified Delphi methodsMultistep global consensus processNominal group techniquePolycystic ovary syndrome (PCOS)Polyendocrine metabolic ovarian syndrome
Figures from the paper
Abstract (AI)
Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome (PCOS), affects one in eight women. However, the term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. Building on an international mandate for change, we outline an unprecedented, rigorous, multistep global consensus process for the name change. Funding and governance were established with engagement of 56 leading academic, clinical, and patient organisations. Using iterative global surveys (with responses from 14 360 people with PCOS and multidisciplinary health professionals from all world regions), modified Delphi methods, nominal group technique workshops, and marketing and implementation analyses, we identified principles prioritising scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and implementation feasibility. An accurate new name was prioritised over retaining the PCOS acronym or a generic name. Implementation approaches prioritised evolution rather than transformation. Preferred terms were polyendocrine, metabolic, and ovarian, reflecting the condition's multisystem pathophysiology, and polyendocrine metabolic ovarian syndrome was the consensus new name. Accuracy was improved by omitting cysts and by capturing endocrine, metabolic, and ovarian dysfunction. A co-designed global implementation strategy, including a transition period, education, and alignment with health systems and disease classification, is under way.
Key Findings
1
A global multistep consensus process renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).
2
Implementation strategy emphasizes evolution over transformation, including a transition period, education, and alignment with health systems and disease classification.
3
Preferred name components—polyendocrine, metabolic, and ovarian—reflect multisystem pathophysiology and avoid stigma by omitting 'cysts'.
4
The consensus process engaged 56 academic, clinical, and patient organisations and collected iterative global survey responses from 14,360 people and multidisciplinary health professionals.
5
The term PCOS was judged inaccurate and misleading because it implies pathological ovarian cysts and obscures endocrine and metabolic features.
Research Object
Polyendocrine metabolic ovarian syndrome (PMOS) as the renamed condition formerly called polycystic ovary syndrome (PCOS)
Research Subject
The consensus-driven renaming process and implementation strategy prioritizing scientific accuracy, stigma reduction, cultural appropriateness, feasibility, and alignment with health systems and disease classification
Publication Details
Publication Date
2026-05-12
Journal
Publisher
ISSN
Cited by
479
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest